Long-Term Efficacy and Safety of Single-Agent Ibrutinib at 3 Years Follow-up in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)
Titel:
Long-Term Efficacy and Safety of Single-Agent Ibrutinib at 3 Years Follow-up in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)
Auteur:
O’Brien, Susan M. Jones, Jeffrey A. Furman, Richard R. Coutre, Steven E. Flinn, Ian W. Burger, Jan A. Blum, Kristie A. Sharman, Jeff P. Wierda, William G. Zhao, Weiqiang Heerema, Nyla A. Johnson, Amy J. Tran, Anh Zhou, Cathy Bilotti, Elizabeth James, Danelle F. Byrd, John C.